Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TET2 mutations in childhood leukemia.
Langemeijer SM, Jansen JH, Hooijer J, van Hoogen P, Stevens-Linders E, Massop M, Waanders E, van Reijmersdal SV, Stevens-Kroef MJ, Zwaan CM, van den Heuvel-Eibrink MM, Sonneveld E, Hoogerbrugge PM, van Kessel AG, Kuiper RP. Langemeijer SM, et al. Among authors: stevens linders e. Leukemia. 2011 Jan;25(1):189-92. doi: 10.1038/leu.2010.243. Epub 2010 Nov 2. Leukemia. 2011. PMID: 21042320 No abstract available.
Acquired mutations in TET2 are common in myelodysplastic syndromes.
Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. Langemeijer SM, et al. Among authors: stevens linders e. Nat Genet. 2009 Jul;41(7):838-42. doi: 10.1038/ng.391. Epub 2009 May 31. Nat Genet. 2009. PMID: 19483684
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH. Aslanyan MG, et al. Among authors: stevens linders e. Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. Epub 2014 Mar 29. Ann Hematol. 2014. PMID: 24994606
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.
Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP, Schnittger S, Haferlach T, Pahl HL, van der Reijden BA, Jansen JH. Kroeze LI, et al. Among authors: stevens linders e. Blood. 2012 Feb 2;119(5):1318-9. doi: 10.1182/blood-2011-07-365213. Blood. 2012. PMID: 22308284 Free article. No abstract available.
Characterization of a genomic region 8 kb downstream of GFI1B associated with myeloproliferative neoplasms.
van Bergen MGJM, van Oorschot R, Bergevoet SM, de Graaf AO, Tönnissen ELRTM, Stevens-Linders E, Neveling K, Jansen PWTC, Baltissen MPA, Vermeulen M, Mandoli A, Martens JHA, Preijers F, Jansen JH, van der Reijden BA. van Bergen MGJM, et al. Among authors: stevens linders e. Biochim Biophys Acta Mol Basis Dis. 2021 Dec 1;1867(12):166259. doi: 10.1016/j.bbadis.2021.166259. Epub 2021 Aug 31. Biochim Biophys Acta Mol Basis Dis. 2021. PMID: 34450246 Free article.